The FDA approved Moderna’s mRNA-1010 (mFLUSIVA), marking the first FDA-authorized flu vaccine designed as an mRNA product. Company and regulator materials tied the decision to positive Phase III data and reported efficacy advantages versus the standard-of-care flu shot, while also noting higher reactogenicity for Moderna’s regimen.